0001415889-24-015754.txt : 20240606
0001415889-24-015754.hdr.sgml : 20240606
20240606162357
ACCESSION NUMBER: 0001415889-24-015754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240604
FILED AS OF DATE: 20240606
DATE AS OF CHANGE: 20240606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hillan Kenneth J.
CENTRAL INDEX KEY: 0001600359
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 241025370
MAIL ADDRESS:
STREET 1: C/O ACHAOGEN, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 371
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER NAME:
FORMER CONFORMED NAME: Hillan Kenneth
DATE OF NAME CHANGE: 20140218
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
form4-06062024_080652.xml
X0508
4
2024-06-04
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001600359
Hillan Kenneth J.
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND
CA
94084
true
false
false
false
0
Common Stock
2024-06-04
4
A
0
25000
0
A
74600
D
Stock Option (Right to Buy)
0.5676
2024-06-04
4
A
0
50000
0
A
2034-06-03
Common Stock
50000
50000
D
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-06-06